New NHS Blood Test Trial Unveiled to Improve early detection for 12 Common Cancers
Our CEO reacts to the news that Secretary of State for Health and Social Care, Wes Streeting, has announced a blood test trial which aims to improve early detection of pancreatic cancer and 11 other cancers
The Secretary of State for Health and Social Care, Wes Streeting, has announced a new blood test trial which aims to help improve the early detection of the 12 most common cancers – including pancreatic cancer. The test, known as miONCO-Dx, works by measuring biomarkers in a blood sample and using AI to identify if cancer is present and if so, where it is located in the body.
Improving early detection is vitally important to improving survival rates for pancreatic cancer. Work in this area is a cornerstone of our research strategy and a number of promising projects are already underway. You can read more about these innovative projects in our research section.
Responding to today’s announcement, Diana Jupp, CEO of Pancreatic Cancer UK, said:
“Right now, it is almost impossible for GPs to diagnose pancreatic cancer in time to save lives because the vital early detection tools they need are missing. We are therefore delighted to see more investment from Government applying cutting-edge science and AI to help make early diagnosis a reality for people affected by the deadliest common cancer.”
If further trials of the miONCO-Dx blood test continue to show promise, it could provide a vital early-warning system to alert doctors of the need to order further investigations.
“There will always be a clear need for tests that are specific to pancreatic cancer. Breath, blood and urine tests are already in development designed to identify people who are experiencing vague initial symptoms of pancreatic cancer – such as indigestion, back or tummy pain – from among those with a far less serious health problem. Used in combination with a tool like miONCO-Dx, they will ensure future patients at the highest risk are referred to hospital quickly, and early giving them the very best chance of receiving lifesaving treatment.
“Research into pancreatic cancer has been overlooked and underfunded for decades because of an outdated perception that it is too difficult to improve outcomes. We are finally on the cusp of real change, but more investment in early detection remains of paramount importance. People affected by this devastating disease deserve more than hope.”